Apotex Inc. v. Gilead Sciences, Inc. et al, No. 3:2018cv06475 - Document 63 (N.D. Cal. 2019)
Court Description: ORDER GRANTING MOTION TO DISMISS [REDACTED]. Signed by Judge Joseph C. Spero on January 31, 2019. (jcslc1S, COURT STAFF) (Filed on 4/23/2019)
Download PDF
<![CDATA[
1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 APOTEX INC., 7 Case No. 18-cv-06475-JCS Plaintiff, 8 v. ORDER GRANTING MOTION TO DISMISS 9 GILEAD SCIENCES, INC., et al., 10 Re: Dkt. No. 28 Defendants. REDACTED United States District Court Northern District of California 11 12 13 14 I. INTRODUCTION Plaintiff Apotex Inc. (“Apotex”) brings an action seeking a declaratory judgment of non- 15 infringement as to United States Patent Nos. 8,106,183 (“ ’183 Patent”) and 9,085,601 (“ ’601 16 Patent”) (collectively, the “patents-in-suit”) in connection with its Abbreviated New Drug 17 Application (“ANDA”) for a Proposed Regadenoson Product (ANDA No. 207604). Apotex 18 named as Defendants Gilead Sciences, Inc. (“Gilead”), which owns the patents-in-suit, and 19 Astellas Pharma US, Inc. (“Astellas Pharma”), the holder of the New Drug Application (“NDA”) 20 for Lexiscan, the product that Apotex seeks to market in generic form. Lexiscan is listed in the 21 Food and Drug Administration’s official publication of approved drugs (“Orange Book”) together 22 with the patents-in-suit. 23 Gilead and Astellas Pharma bring a Motion to Dismiss (“Motion”) in which they assert 24 that: 1) the claims against Astellas Pharma should be dismissed because this Court does not have 25 personal jurisdiction over it and venue here is improper; and 2) all of Apotex’s claims must be 26 dismissed because it has failed to join Astellas US LLC (“Astellas LLC”), which is a required 27 party, and Astellas LLC cannot be joined in this action because, like Astellas Pharma, Astellas 28 LLC is not subject personal jurisdiction in this Court. In its Opposition, Apotex does not dispute 1 that there is no personal jurisdiction as to Astellas Pharma and stipulates to the dismissal of that 2 entity without prejudice.1 Apotex also does not dispute that the Court does not have personal 3 jurisdiction over Astellas LLC. Therefore, the only remaining issue is whether the Motion should 4 be granted and the action dismissed on the basis that Apotex failed to join (and cannot join) a 5 necessary party. The Court finds that the Motion is suitable for determination without oral 6 argument and therefore vacates the hearing set for Friday, February 8, 2019 at 9:30 a.m. pursuant 7 to Civil Local Rule 7-1(b). For the reasons stated below, the Motion is GRANTED.2 8 II. United States District Court Northern District of California 9 BACKGROUND A. Factual Background 10 Astellas Pharma markets a product called “Lexiscan® and is the NDA holder for that 11 product.” Complaint ¶ 34. Lexiscan is a “single-dose prefilled syringe” filled with a “clear, 12 colorless solution containing regadenoson 0.4 mg/5 mL (0.08 mg/mL).” Opposition, Ex. I. The 13 patents-in-suit, which are owned by Gilead, are listed in the Orange Book as covering Lexiscan. 14 Complaint ¶¶ 35-36, 39 & Exs. A & B (listing Gilead as assignee on patents-in-suit). [REDACTED], Astellas LLC’s predecessor, Fujisawa Healthcare, Inc. (“FHI”), entered 15 16 into a Collaboration and License Agreement (“CLA”) with Gilead’s predecessor, CV 17 Therapeutics, Inc. (“CVT”), [REDACTED] 18 Johnston Decl. ¶ 5 19 20 (“Astellas US LLC is the successor-in-interest to Fujisawa Healthcare Inc.”) [REDACTED] ; see also Reply, Ex. 4 (Gilead Form 10-K for fiscal year ending December 31, 2009) at 2 21 22 (stating that Gilead acquired CVT in 2009). [REDACTED] 23 24 25 26 27 28 1 Because the Court finds that the entire action is subject to dismissal, it need not reach the question of whether it is appropriate to dismiss Astellas Pharma pursuant to Rule 21 of the Federal Rules of Civil Procedure based on misjoinder. 2 The parties have consented to the jurisdiction of the undersigned magistrate judge pursuant to 28 U.S.C. § 636(c). 2 United States District Court Northern District of California 1 [REDACTED] 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 3 1 2 3 4 Statutory Framework Under the Hatch-Waxman Act When a company or individual files an NDA with the Food and Drug Administration 5 (“FDA”), it must, inter alia, identify those patents “with respect to which a claim of patent 6 infringement could reasonably be asserted if a person not licensed by the owner engaged in the 7 manufacture, use, or sale of the drug.” 21 U.S.C. § 355(b)(1). After an NDA is approved, the 8 FDA publishes the enumerated patents in the Orange Book. Id. 9 United States District Court Northern District of California B. The Hatch-Waxman Act allows a generic drug manufacturer to seek expedited approval to 10 market a generic version of an already-approved drug by submitting an ANDA. Glaxo, Inc. v. 11 Novopharm, Ltd., 110 F.3d 1562, 1568 (Fed. Cir. 1997); see also 21 U.S.C. § 355(j)(1) (“Any 12 person may file with the Secretary an abbreviated application for the approval of a new drug.”). 13 As part of the application process, the applicant is required to certify that the proposed product 14 will not infringe any patents listed for the drug in the Orange Book, or that those patents are 15 invalid. 21 U.S.C. § 355(j)(2)(A)(vii). The applicant also must send what is referred to as a 16 “Paragraph IV Notice Letter” to the owner of the patent and to the NDA holder of the approved 17 drug informing them that the ANDA applicant seeks to manufacture that drug in generic form and 18 certifying that the patent “is invalid or will not be infringed by the manufacture, use, or sale of the 19 new drug for which the application is submitted.” 21 U.S.C. § 355(j)(2)(A)(vii)(IV); see also 21 20 U.S.C. § 355(j)(2)(B)(iii) (specifying that notice must be given to “each owner that is the subject 21 of the certification” and “the holder of the approved application . . . for the drug that is claimed by 22 a patent or a use of which is claimed by the patent . . . .”). 23 Under the Hatch-Waxman framework, the ANDA applicant must wait at least 45 days after 24 the Paragraph IV Notice Letters have been received before bringing an action for a declaratory 25 judgment against the patent owner or holder for a declaration of noninfringement or invalidity. 21 26 U.S.C. § 355(j)(5)(C)(i)(I). During that period, the recipient of a Paragraph IV Notice Letter may 27 bring an infringement action against the ANDA applicant, resulting in a 30-month stay of the FDA 28 approval process. 21 U.S.C. § 355(j)(5)(B)(iii). On the other hand, if no recipient of the 4 1 Paragraph IV Notice brings an infringement action within the 45-day period, the ANDA applicant 2 may bring a declaratory judgment action against the patent owner or the holder of the NDA 3 seeking a declaration of noninfringement and/or invalidity under 28 U.S.C. § 2201. 21 U.S.C. § 4 355(j)(5)(C)(i)(II). This subsection of the Hatch-Waxman Amendments further provides that “[a] 5 civil action referred to in this subclause shall be brought in the judicial district where the defendant 6 has its principal place of business or a regular and established place of business.” Id. 7 C. On August 31, 2018, Apotex sent Paragraph IV Notice Letters to Astellas Pharma and 8 United States District Court Northern District of California 9 Procedural Background and Related Litigation Gilead; the letters were received on September 4, 2018. Opposition, Exs. B (Paragraph IV Notice 10 Letter, C (Gilead Receipt) & D (Astellas Pharma Receipt). Neither Gilead nor Astellas Pharma 11 brought an infringement action within 45 days of receiving Apotex’s notice, which expired on 12 October 19, 2018. On October 23, 2018, Apotex filed the instant action, filing a complaint 13 seeking a declaratory judgment of non-infringement against Gilead and Astellas Pharma with 14 respect to the patents-in-suit (the ’183 and ’601 patents). 15 On October 25, 2018, Astellas Pharma, Astellas LLC, and Gilead jointly filed a complaint 16 for patent infringement in the District of Delaware against Apotex asserting that Apotex’s generic 17 drug will infringe the ’183 and ’601 patents. See United States District Court for the District of 18 Delaware, Civil Action No. 18-cv-1675 (“the Delaware Action”). On the same day, Gilead and 19 the two Astellas entities filed actions against Sandoz, Inc. (Civil Action No. 18-cv-1676), Sun 20 Pharma Global FZE (Civil Action No. 18-cv-1677) and Wockhardt Bio AG and Wockhardt USA 21 LLC (Civil Action No. 18-cv-1678) based on ANDAs filed by those companies to manufacture 22 generics of Lexiscan. All of these cases have been related by the Delaware District Court. 23 D. Contentions of the Parties 24 In the Motion, Defendants argue that this case must be dismissed pursuant to Rules 25 12(b)(7) and 19 of the Federal Rules of Civil Procedure for failure to join a required party, 26 namely, Astellas LLC. Motion at 12. Because questions of joinder are not unique to patent law, 27 they assert, Ninth Circuit law governs this question rather than the law of the Federal Circuit. Id. 28 In the Ninth Circuit, a case must be dismissed under Rule 19 where: 1) the absent party is 5 United States District Court Northern District of California 1 required; 2) joinder of that party is not feasible; and 3) the party is indispensable. Id. at 12 (citing 2 EEOC v. Peabody W. Coal Co., 400 F.3d 774, 779-80 (9th Cir. 2005)). 3 According to Defendants, Astellas LLC is required because it is an exclusive licensee of 4 the patents-in-suit. Id. at 13 (citing Aspex Eyewear v. Miracle Optics, Inc., 434 F.3d 1336, 1344 5 (Fed. Cir. 2006)). Defendants further assert that Astellas LLC cannot be joined because this Court 6 does not have personal jurisdiction over that entity. Id. at 13-14. Finally, Defendants argue that 7 Astellas LLC is indispensable because: 1) any adverse judgment by this Court will prejudices 8 Astellas LLC; 2) there is no way to avoid such prejudice as any judgment in this action will 9 impact the scope of Astellas LLC’s patent rights; 3) judgment in this action will be inadequate 10 because it will not afford complete relief and raises the risk of multiple lawsuits with inconsistent 11 outcomes; and 4) Apotex will not be prejudiced by dismissal of this action because all necessary 12 parties have already consented to venue in the Delaware Action, where Apotex can bring 13 counterclaims for noninfringement and invalidity. Id. at 13-16. 14 In its Opposition, Apotex rejects Defendants’ assertion that dismissal is required under 15 Rule 19. First, it argues that the Hatch-Waxman provision that authorizes a civil action for 16 declaratory relief, 21 U.S.C. § 355(j)(5)(C)(II), is the “controlling statute” and that it is undisputed 17 that Apotex has met the requirements of that section for bringing a civil action against Gilead; it 18 further contends the provision is clear that Astellas Pharma is not a required party and therefore 19 can be dropped from the case (as Apotex seeks to do). Id. at 7-8. Finally, Apotex argues that the 20 Hatch-Waxman Act does not require ANDA applicants to give notice to exclusive licensees or 21 make them defendants in a civil action brought under 21 U.S.C. § 355(j)(5)(C)(II). Id. at 16. 22 Second, Apotex contends the cases upon which Defendants rely for the proposition that an 23 exclusive licensee is a required party is not on point because they do not involve actions seeking 24 declaratory judgment. Id. at 16-18. It further contends that Defendants’ reliance on Rule 19 is 25 misplaced because Rule 19 cannot be used to modify the substantive rights afforded under the 26 Hatch-Waxman Amendments. Id. at 18-19. In support of this argument, Apotex cites to 28 27 U.S.C. § 2072 (providing that the Federal Rules of Civil Procedure “shall not abridge, enlarge or 28 modify any substantive rights”) and Rule 82 of the Federal Rules of Civil Procedure (providing 6 1 that the Federal Rules of Civil Procedure “do not extend or limit the jurisdiction of the district 2 courts or the venue of actions in those courts”). Id. at 18. Apotex also argues that Astellas LLC 3 cannot be “indispensable” for the same reason it cannot be a required party, namely, because a 4 licensee is not a required party under Hatch-Waxman and Defendants cannot rely on Rule 19 to 5 modify Apotex’s substantive right to maintain an action for declaratory relief under Hatch- 6 Waxman against Gilead alone. Id. at 19. Apotex also argues that where courts have reached the question of whether an exclusive United States District Court Northern District of California 7 8 licensee is an indispensable party in an action for declaratory judgment they have found that they 9 are not. Id. at 20. 10 Finally, Apotex questions whether Astellas LLC is, in fact, an exclusive licensee of Gilead. 11 Id. at 21. It asserts that the patents claim a crystalline form of regadenoson, whereas Lexiscan is a 12 solution, and further argues that “there is no chain of evidence in the limited record provided by 13 Defendants connecting the dots between the original licensing agreement, the Gilead [’183] and 14 [’601] Patents, any Astellas LLC use of those patents, and, ultimately, Astellas Pharma’s marketed 15 product in the United States (LEXISCAN®).” Id. 16 Apotex asserts, Defendants have not shown that there is any conflict of interest between Gilead 17 and Astellas LLC that could justify dismissal of this action. Id. 18 III. Even if such a connection were established, ANALYSIS 19 A. 20 Pursuant to Rule 12(b)(7) of the Federal Rules of Civil Procedure, a court may dismiss an Legal Standards Under Rule 12(b)(7) and Rule 19 21 action for failure to join a required party under Rule 19. Rule 19, in turn, permits a court to 22 dismiss an action where a party is “required,” joinder of that party is not feasible, and the court 23 concludes “in equity and good conscience” that the action should not proceed between the existing 24 parties, that is, that the party is indispensable. 25 26 B. Whether Rule 19 Applies to Declaratory Judgment Actions Under HatchWaxman Apotex contends Rule 19 of the Federal Rules of Civil Procedure does not apply to a 27 declaratory judgment brought under 28 U.S.C. § 2201 (the Declaratory Judgment Act) and the 28 7 1 United States District Court Northern District of California 2 Hatch-Waxman Act. The Court disagrees. First, the Hatch-Waxman Act places certain limitations on an ANDA applicant’s ability to 3 bring an action for declaratory judgment but does not create an independent cause of action; 4 rather, it simply permits ANDA applicants to bring an action under the Declaratory Judgment Act 5 when the requirements of Hatch-Waxman have been satisfied. See 21 U.S.C. § 355(j)(5)(C). 6 Moreover, it is well-established that “the operation of the Declaratory Judgment Act is procedural 7 only.” Aetna Life Ins. Co. of Hartford, Conn. v. Haworth, 300 U.S. 227, 240 (1937). In other 8 words, neither the Hatch-Waxman provision that permits an ANDA applicant to bring a 9 declaratory judgment action nor the Declaratory Judgment Act itself creates any independent 10 substantive right or expands federal jurisdiction. Consequently, neither 28 U.S.C. § 2702 (which 11 provides that the Federal Rules of Civil Procedure “shall not abridge, enlarge or modify any 12 substantive right”) nor Rule 82 of the Federal Rules of Civil Procedure (which provides that 13 federal jurisdiction may not be limited or extended by the Federal Rules of Civil Procedure) 14 supports Apotex’s argument that Rule 19 is not applicable in this case. 15 The Court also rejects Apotex’s reliance on the language of Section 355(j)(5)(C)(i)(II) in 16 support of its assertion that Rule 19 cannot be applied in this case. While that section permits an 17 ANDA applicant to bring a civil action for a declaratory judgment against the patent owner or the 18 NDA holder, nothing in that section suggests that Congress intended to limit the normal 19 procedural rules governing joinder of required parties with respect to such actions or to modify the 20 jurisdictional requirements under substantive patent law. To the contrary, such a reading of this 21 section would be at odds with the doctrine of prudential standing that generally applies in patent 22 cases. For example, even though this provision may authorize an ANDA applicant to seek a 23 declaratory judgment only as to an NDA holder (because of the “owner or holder” language in it), 24 there is no reason to conclude that Congress intended to abrogate the established rule that a party 25 that challenges a patent must include the proper parties as defendants. See, e.g., A123 Sys., Inc. v. 26 Hydro-Quebec, 626 F.3d 1213, 1217 (Fed. Cir. 2010) (noting that “[u]nder long-standing 27 prudential standing precedent” applicable in infringement actions, “an accused infringer must 28 likewise join both the exclusive licensee and the patentee in a declaratory action”); see also Enzo 8 1 APA & Son, Inc. v. Geapag A.G., 134 F.3d 1090, 1094 (Fed. Cir. 1998) (finding that “the court 2 lacks jurisdiction over [accused infringer’s] declaratory judgment claims under Fed. R. Civ. P. 19 3 for nonjoinder” where patentee was not joined as defendant); Abraxis Bioscience, Inc. v. Navinta 4 LLC, 625 F.3d 1359, 1367 (Fed. Cir. 2010) (dismissing infringement action brought by NDA 5 holder under the Hatch-Waxman Act where NDA holder “lacked standing on the day it filed the 6 action”). United States District Court Northern District of California 7 Likewise, the fact that Section 355(j)(5)(C)(i)(II) does not expressly require that exclusive 8 licensees must be joined in an action under that section is of no moment; to the extent an exclusive 9 licensee is a required party under the rules of standing that apply in patent cases, the Court 10 concludes that those apply regardless of whether they are expressly incorporated into the Hatch- 11 Waxman Act. Similarly, while Section 355(j)(5)(C)(i)(II) provides that “[a] civil action referred 12 to in this subclause shall be brought in the judicial district where the defendant has its principal 13 place of business or a regular and established place of business,” the Court interprets that 14 provision only as establishing venue as to the “the owner or holder [of the NDA]” named as a 15 defendant and not as abrogating the joinder rules set forth in Rule 19 or any other requirements of 16 the Federal Rules of Civil Procedure. 17 Accordingly, the Court concludes that Rule 19 applies in this case. 18 C. 19 20 Whether Rule 19 Requires Dismissal of the Action 1. Whether Astellas LLC is an exclusive licensee As a preliminary matter, Apotex suggests that Astellas LLC is not an exclusive licensee for 21 the purposes of determining whether it is a required party. Among other things, it suggests that 22 the CLA may not make Astellas LLC an exclusive licensee under the patents-in-suit because 23 Lexiscan is a solution rather than a crystal and therefore, is not covered by the patents-in-suit. The 24 Court rejects this argument. The evidence in the record, summarized above, shows that Astellas 25 LLC holds an exclusive license [REDACTED] 26 solution used in Lexiscan, and Lexiscan is listed in the Orange Book along with the patents-in- 27 suit. Apotex’s argument that Lexiscan falls outside of the scope of the claims of the patents-in- 28 suit goes to the merits of the case, not to whether Astellas LLC is an exclusive licensee. . Regadenoson is the 9 United States District Court Northern District of California 1 2. Whether Astellas LLC is a required party 2 In an action in which a patent is challenged, an exclusive licensee is a necessary party and 3 therefore must be joined. Aspex Eyewear, Inc. v. Miracle Optics, Inc., 434 F.3d 1336, 1344 (Fed. 4 Cir. 2006) (citing Independent Wireless Tel. Co. v. Radio Corp., 269 U.S. 459, 466 (1926) (both 5 the owner and the exclusive licensee are generally necessary parties in an action in equity)); see 6 also Alfred E. Mann Found. For Sci. Research v. Cochlear Corp., 604 F.3d 1354, 1360 (Fed. Cir. 7 2010) (explaining that under Aspex, “[w]hen there is an exclusive license agreement, as opposed to 8 a nonexclusive license agreement, but the exclusive license does not transfer enough rights to 9 make the licensee the patent owner, either the licensee or the licensor may sue, but both of them 10 generally must be joined as parties to the litigation.”). This rule applies in declaratory judgment 11 actions as well as in actions for patent infringement. See A123 Sys., Inc., 626 F.3d at 1217 (“an 12 accused infringer must likewise join both the exclusive licensee and the patentee in a declaratory 13 action”) (citing Enzo APA & Son, Inc. v. Geapag A.G., 134 F.3d 1090, 1094 (Fed.Cir.1998)). 14 Under this authority, the Court finds that because Astellas LLC is an exclusive licensee, it is a 15 required party in Apotex’s declaratory judgment action. 16 3. Whether Astellas LLC can be joined 17 Apotex does not dispute that Astellas LLC is not subject to this Court’s jurisdiction. 18 Therefore, the Court finds that it is not feasible to join Astellas LLC in this action. 19 4. Whether Astellas LLC is an indispensable party 20 In determining whether Astellas LLC is an indispensable party, courts consider the 21 following nonexclusive factors: (1) “to what extent a judgment rendered in the person’s absence 22 might be prejudicial to the person or those already parties;” (2) “the extent to which, by protective 23 provisions in the judgment, by the shaping of relief, or other measures, the prejudice can be 24 lessened or avoided;” (3) “whether a judgment rendered in the person’s absence will be adequate;” 25 and (4) “whether the plaintiff will have an adequate remedy if the action is dismissed for 26 nonjoinder.” Fed. R. Civ. P. 19(b). The Court concludes that all of these factors point towards 27 dismissal of this action. 28 First, the Court finds that an adverse judgment declaring that Apotex’s regadenoson 10 1 product does not infringe the patents-in-suit would severely prejudice Astellas LLC. 2 [REDACTED] 3 If Apotex markets a 4 5 competing product before the patents-in-suit expire, those sales are likely to have a substantial 6 negative impact [REDACTED] 7 interests are not identical to Gilead’s as [REDACTED] . Further, Astellas LLC’s ; the risk posed by a United States District Court Northern District of California 8 9 competing generic product will therefore have a disproportionately negative impact on Astellas 10 LLC as compared to Gilead. It is likely because the interests of Astellas LLC and Gilead are not 11 identical that [REDACTED] 12 the Court concludes Astellas LLC will be prejudiced if it is not joined in this action. 13 . Therefore, Second, the Court is not aware of any measures that might be taken to eliminate or reduce 14 this prejudice as Astellas LLC would be deprived of its ability to protect its interest in defending 15 the patents-in-suit if this case were to go forward. 16 Third, because Astellas LLC is a required party, any judgment entered in this action is 17 likely to be inadequate because it will not sufficiently address Astellas LLC’s interests. Because 18 Astellas LLC has standing as an exclusive licensee to pursue its own action (at least if the patentee 19 is also joined), the result is likely to be piecemeal litigation. Indeed, there is already a parallel 20 case in Delaware in which Astellas LLC is a party (along with the patentee and the NDA holder), 21 involving the same patents and product. Because all of the required parties are before the District 22 Court of Delaware, the Court concludes that the challenges raised by Apotex in this action can 23 only be fully resolved in the Delaware Action. For the same reason, the Court finds that Apotex 24 will have an adequate remedy if this action is dismissed for failure to join a required party. 25 For these reasons, the Court concludes that Astellas LLC is an indispensable party under 26 Rule 19. The Court further concludes that under Rule 19, this action should not proceed among 27 the existing parties. 28 11 1 2 IV. CONCLUSION For the reasons stated above, the Court GRANTS the Motion and dismisses this action 3 without prejudice for failure to join Astellas LLC, which is a required party. The Clerk is 4 instructed to close the file. 5 IT IS SO ORDERED. 6 7 Dated: January 31, 2019 8 9 10 ______________________________________ JOSEPH C. SPERO Chief Magistrate Judge United States District Court Northern District of California 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 12
]]>
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You
should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
